Certainties and Sensitivity Analysis of the Global Economy: A GDP by End-Use Approach
Journal of Global Economics & Sustainable Development · 13.11.2026 · 2 (1) · 34-47
DOI: 10.54536/jgesd.v2i1.8948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Global Economics & Sustainable Development, online erschienen am 13.11.2026. Verfasst von Jorge Monray. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This research first analyses the evolution of four GDP by end-use variables (Household Consumption, Government Spending, Exports, and Imports) for the top 40 economies in the world, covering up to 90% of the global economy. The first part of the research project is determined by a longitudinal analysis of 40+ years, resulting in a linear regression to the expected GDP value of each nation for 2030. Secondly, both a Monte Carlo and a sensitivity simulation analysis are performed. The analysis reveals that the most sensitive variables that contribute to the dispersion of the GDP by end-use future results are imports, followed by exports. Also, Household Consumption appears with a small presence, while the Government Spending factor shows no sensitivity in the model. This research demonstrates the crucial importance of adjusting the balance of trade.
Zitieren
APA
Monray, J. (2026). Certainties and Sensitivity Analysis of the Global Economy: A GDP by End-Use Approach. Journal of Global Economics & Sustainable Development, 2(1), 34-47. https://doi.org/10.54536/jgesd.v2i1.8948
Vancouver
Monray J. Certainties and Sensitivity Analysis of the Global Economy: A GDP by End-Use Approach. Journal of Global Economics & Sustainable Development. 2026;2(1):34-47. doi:10.54536/jgesd.v2i1.8948
BibTeX
@article{Monray2026,
author = {Monray, Jorge},
title = {Certainties and Sensitivity Analysis of the Global Economy: A GDP by End-Use Approach},
journal = {Journal of Global Economics & Sustainable Development},
year = {2026},
volume = {2},
number = {1},
pages = {34--47},
doi = {10.54536/jgesd.v2i1.8948}
}
EUVIMED